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BACKGROUND. Prostate cancer frequently metastasizes to bone. However, unlike many
other tumors that produce osteolytic lesions, prostate cancer produces osteoblastic lesions
through unknown mechanisms. In the current study, we explored the ability and mechanism
of an osteotropic prostate cancer cell line (C4-2B) to induce mineralization.
METHODS. C4-2B cells were grown in promineralization media. Mineral deposition was
characterized using von Kossa staining, calcium retention, alizarin red staining, Raman
spectroscopy, and electron microscopy. Expression of osteoblast-related proteins was
determined by RT-PCR. The nuclear level of the bone-speci®c transcription factor Cbfa1
was determined using western analysis and the effect of inhibiting Cbfa1 function, using a
``decoy'' Cbfa1 response element oligo, on mineralization was determined.
RESULTS. The studies demonstrated that C4-2B cells, but not its nonosteotropic parent cell
line LNCaP, has an osteoblastlike phenotype including production of alkaline phosphatase,
osteocalcin, osteonectin, bone sialoprotein, osteoprotegerin (OPG), and OPG ligand. Most
importantly, the C4-2B cells produced hydroxyapatite mineral in vitro. Furthermore, C4-2B
cells expressed high nuclear levels of the bone-speci®c transcription factor Cbfa1, compared to
LNCaP cells, which accounts for their ability to produce bone-speci®c proteins. Inhibition of
Cbfa1, using decoy DNA Cbfa1 response elements, abrogated the ability of C4-2B to produce
mineral. Finally, we determined that C4-2B cells express bone morphogenic protein-7, a
known inducer of Cbfa1 expression.
CONCLUSIONS. These data demonstrate a novel mechanism through which prostate cancer
cells may directly contribute to the osteoblastic component that characterize their skeletal
metastatic lesions. Prostate 47:212±221, 2001. ß 2001 Wiley-Liss, Inc.
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INTRODUCTION
Prostate carcinoma frequently metastasizes to bone
[1] resulting in both osteoblastic and osteolytic lesions
[2]. The mechanism through which prostate carcinoma
induces osteoblastic lesions are currently not de®ned.
To understand the mechanism of skeletal metastasis,
several animal models of skeletal metastasis or intra-
osseous tumor growth using human prostate cancer
cell lines injected subcutaneously (s.c.), orthotopically
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[3], intravenously (i.v.) with/without inferior vena
cava occlusion [4,5] or intraosseously [6,7] have been
developed.
The LNCaP cell-derived series of human prostate
cancer cell lines described by Thalmann et al. [3]
closely mimic clinical prostate cancer progression.
Speci®cally, the tumors secrete prostate-speci®c anti-
gen (PSA), progress from androgen dependence to
androgen independence and develop osteoblastic
skeletal metastases. One of the cell lines, C4-2B, was
isolated from metastatic prostate cancer cell lesions
found in the lumbar spine of an athymic murine host.
When injected orthotopically, C4-2B cells produce
osteoblastic metastases in the lumbar spine. Thus, C4-
2B cells provide a model to explore the mechanisms
through which osteoblastic lesions are created.
Koeneman et al. [1] proposed that bone is a highly
restricted and protective environment that prohibits
the growth and survival of cancer cells and that in
order to thrive in the bone microenvironment, cancer
cells must acquire ``osteoblastlike'' properties. In
agreement with this postulation, we hypothesized
that C4-2B cells gain an osteoblast phenotype. Accord-
ingly, the aim of this study was to evaluate if the
osteotropic C4-2B cells gained characteristics of oste-
oblasts compared to their parental LNCaP cell line.
MATERIALSANDMETHODS
Cell Culture
The human prostate cancer cell lines LNCaP
(American Type Tissue Collection, Manassas, VA)
were grown in RPMI-1640 media with 10% fetal bovi-
ne serum (FBS) and antibiotics (penicillin 1,000 U/ml,
streptomycin 10 mg/ml) (Gibco, Grand Island, NY).
C4-2B cells (Urocor) were grown in T-medium (80%
Dulbecco's modi®ed Eagle's medium (Gibco), 20%
F12K (Irving Scienti®c, Santa Ana, CA), 3 g/liter
NaHCO3, 100 u/liter penicillin G, 100 mg/ml strepto-
mycin, 5 mg/ml insulin, 13.6 pg/ml triiodothyronine,
5 mg/ml transferrin, 0.25 mg/ml biotin, 25 g/ml
adenine), supplemented with 5% FBS [8]. Primary
osteoblastic cells were derived from human cancellous
bone explants (9). Bone specimens were collected from
human subjects undergoing hip replacement. Trabe-
cular bone chips were washed extensively in phos-
phate buffered saline (PBS) to remove bone marrow,
and then treated by sequential digestion with Colla-
genase P (Boehringer Mannheim, Indianapolis, IN).
Collagenase-released cells were plated and cultured in
a medium containing an 1:1 mixture of Dulbecco's
Modi®ed Eagle's medium and Ham's formula 12
medium (DMEM-F12) (Gibco) supplemented with
20% FBS and antibiotics. The medium was changed
twice per week. These cells expressed the phenotype
of mature osteoblastic cells. MC 3T3-E1 cells were
grown in the same media in which primary osteoblasts
were grown. To induce mineral production, cells were
supplemented with 10 mM b-glycerophosphate (Sigma
Chemical Co., St. Louis, MO) and 50 mg/ml L-ascorbic
acid (Sigma) for the indicated time.
Detection ofMineral
Calcium content in culture (5 104 cells/well of
6-well plate) was measured using standard bioche-
mistry (Calcium assay kit 587-A; Sigma). To stain
mineral, cultures were ®xed in 95% ethanol at 37C for
5 min, rehydrated, then stained using von Kossa's
method as previously described [10]. For the alizarin
red assay, the medium was removed and the cells
were air dried, ®xed in 50% ethanol three times, then
stained with alizarin red (Sigma; 100 mg/ml in 0.01%
NaOH) for 5 min. After a PBS wash, retained dye was
extracted in a solution of 20% methanol and 10% acetic
acid, then measured at A450.
RamanMicroscopy
The prostate cancer cell cultures were grown on
quartz cover slips (Esco Products). Once harvested, the
cover slips were placed on a quartz slide and subjected
to Raman spectroscopy as previously described [11].
In the current application, the excitation source
was either a Ti-sapphire CW laser (Spectra Physics)
pumped by a Nd-YVO4 laser (Spectra Physics) and
tuned to 785.0 nm or a 785.0 nm diode laser (SDL). A
20/0.75 NA Fluar objective (Zeiss) was used to
focus the laser excitation to a point on the cell cultures.
The backscattered Raman scatter was focused into an
axial transmissive spectrograph (Kaiser Optical Sys-
tems, Inc. HoloSpec f/1.8i, 25-mm slit) and dispersed
onto either a liquid-nitrogen cooled, front-illuminated
charge-coupled device (CCD) camera (Photometrics)
or a liquid-nitrogen cooled, back-thinned CCD camera
(Princeton Instruments). The point microspectroscopy
prostate cancer cell culture data were analyzed using
GRAMS32 software (Galactic Industries Corporation)
and MatLab software (MathWorks, Inc.). The spectra
were corrected only for outliers. Once Raman-shifted,
the spectra were baselined using a quadratic ®t.
ElectronMicroscopy
Cell monolayers were ®xed in 2.5% glutaraldehyde
in 0.1 M Sorensen's buffer, pH 7.4. They were
post®xed in osmium tetroxide (1%) in buffer followed
by dehydration in a graded series of ethanol then
embedded in Epon. Ultrathin sections were stained
with uranyl acetate and lead citrate and viewed on
a Philips CM100 transmission electron microscope
(TEM) at 60 kV.
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Alkaline Phosphatase Staining
Histochemical alkaline phosphatase staining was
performed using the Sigma Diagnostics Phosphatase
kit (Catalog No. 86, Sigma Diagnostic, Inc, St. Louis,
MO) as directed by the manufacturer. Brie¯y, the
adhesive LNCaP, C4-2B cells and primary human
osteoblasts were washed with HBSS, ®xed with
citrate-acetone-formaldehyde ®xative solution for 30
sec, then stained with alkaline-dye mixture at room
temperature for 15 min. The kit is using Naphthol AS-
MS phosphate substrate and Fast Red Violet B for the
enzyme activity determination. They were then coun-




Total RNA was isolated from cells using TRIzol
method as directed by the manufacturer (Life Tech-
nologies, Gaithersburg, MD). Due to the small
quantities of osteoprotegerin (OPG) mRNA we used
real-time PCR for evaluation of OPG mRNA levels.
One microgram of total RNA was subject to real-time
PCR (LightCycler, Roche Diganostics, Indianapolis,
IN) using the SYBR Green I RNA ampli®cation kit
(Roche Diagnostics). PCR reactions were mixed and
incubated at room temperature for 10 min then
subjected to 45 cycles of 94C, 5 sec; 55C, 10 sec;
72C, 1 min. The OPG primers are described elsewhere
[12]. An internal titration analysis on GAPDH was
done and we obtained a linear ampli®cation suggest-
ing the integrity of the sample RNA.
The remaining mRNA targets were evaluated by
standard RT-PCR and gel electrophoresis. Cbfa1
primers were as previously described [13]. Glyceral-
dehyde phosphate dehydrogenease (GAPDH) primers
used were sense, 5 0-TGAAGGTCGGTGTGA-ACGG-
ATTTGGTC-3 0 and antisense, 5 0-CATGTAG-GCCAT-
GAGGTCCACCAC-3 0 to generate a 960-bp fragment.
Bone morphongenic protein-7 (BMP-7) primers used
were sense; 5 0-AGCCCGGGTAGCGCGTAGAG-3 0
and antisense, 5 0-GCGCCGGTGGATGAAGCTCGA-
3 0 to generate a 165 bp fragment. Bone sialoprotein
(BSP) primers used were sense, 5 0-TCAGCATTTTGG-
GAATGGCC-3 0 and antisense, 5 0-GAGGTTGTTGT-
CTTCGAGGT-3 0 to generate a 660 bp fragment.
Osteocalcin (OCN) primers used were sense, 5 0-CAT-
GAGAGCCCTCACA-3 0 and antisense, 5 0-CAGATCC-
CACAGCGAGA-3 0 to generate a 495 bp fragment.
Receptor activator of NFkB ligand (RANKL) primers
used were sense, 5 0-GGTCGGGCAATTCTGAATT-3 0
and antisense, 5 0-GGGAATTACAAAGTGCACCAG-
3 0 to generate an 810 bp fragment. Osteonectin (OSN)
primers used were sense, 5 0-ATGAGGGCCTGGAT-
CTTCTT-3 0 and antisense, 5 0-CTGCTTCTCAGTCAG-
AAGGT-3 0 to generate a 580 bp fragment. b2-
microglobulin, sense, 5 0-ATGCC-TGCCGTGTGAAC-
CATGT-3 0, and antisense 5 0-AGAGCTACCTGTGG-
AGCAACCT-3 0 to generate a 300 bp fragment. Target
gene products were subjected to 38 cycles (except
BMP-7 and b2-microglobulin which were ampli®ed 29
cycles) using AmpliTaq Gold (Applied Biosystems,
California) and cycling parameters of 95C, 6 min, then
cycling at 94C, 15 sec; 55C, 30 sec; 72C, 1 min and
72C, 3 min for the ®nal extension.
Nuclear Lysate Preparation and
Western BlotAnalysis
Nuclear protein extract from cells was prepared as
described previously (Lin et al., paper submitted).
Brie¯y, cells were harvested after being washed twice
in PBS buffer. For nuclei preparation, cells were
resuspended in hypotonic buffer (10 mM HEPES±
KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP40)
and incubated on ice for 10 min. Nuclei were
precipitated with 3000g centrifugation at 4C for
10 min. After washing once with hypotonic buffer,
the nuclei were lysed in the lysis buffer (50 mM Tris±
HCl pH 8.0, 150 mM NaCl, 1% Triton X-100) and
incubated on ice for 30 min. The nuclear lysates were
pre-cleared by 20,000g centrifugation at 4C for 15 min.
Protein concentration was measured by Bradford
assays. Western blot analysis was performed as
previously described (Lin and Keller, paper sub-
mitted) with rabbit anti-Cbfa1 (AML3) (Oncogene
Research Product, Cambridge, MA) and visualized
with chemiluminescence.
Transfection andDNADecoy
DNA oligo sequences were designed based on the
previously reported Cbfa1 response element sequence
[14]. Wild-type Cbfa1 decoy DNA oligos were: sense,
5 0-TCGAGGATATTTGCGGTTAGCA-3 0 and antisense,
5 0-TCGATGCTAACCGCAAATATCC-3 0. Mutant Cbfa1
decoy DNA oligos were: sense, 5 0-TCGAGGATATTG-
CCAATTAGCA-3 0 and antisense, 5 0-TCGATGCTAA-
TTGGCAATATCC-3 0. The individual oligos were
annealed to their respective complementary oligos and
then used to transfect cells as previously described [15]
using a lipid-based transfection reagent (FuGENE6;
Roche Diagnostics).
RESULTS
CalciumContentof Prostate CancerCell Line
Grown in PromineralizationMedia
The primary function of osteoblasts is to form bone.
Thus, to determine if prostate cancer cells have the
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capacity to form bone, we cultured nonosteotropic
LNCaP cells and their osteotropic derivative C4-2B
cells in promineralization media. Promineralization
media contained (a) ascorbic acid, which allows for
production of skeletal-type extracellular matrix from
osteoblasts and (b) a phosphate source for hydro-
xyapatite formation. Nonosteoblastic cells do not
produce mineral in this media (data not shown). After
incubation in promineralizing media, mineralized
calcium content in the cultures was measured. Due
to the variation with the data we can only detect a
trend (P value 0.0861). Data for LNCaP at the other
time point was lower than that of 20-day old culture
(date not shown). In contrast to LNCaP cells, which
produced a mild increase in absolute levels of calcium,
the C4-2B cells produced approximately an eight-fold
increase of mineralized calcium (Fig. 1). These levels
were ®ve-fold greater than that induced by LNCaP
cells and comparable to those that osteoblasts MC 3T3-
E1 produce in these conditions (Fig. 1). These data
suggest that C4-2B cells gain the ability to sequester
mineral compared to LNCaP cells.
Alizarin Red Retention of Prostate Cancer
Cell LineGrewin PromineralizationMedia
To quantify the mineralized calcium retention in the
culture, we performed alizarin red staining. Strong
alizarin red staining was identi®ed in C4-2B cultures
(Fig. 2A) whereas LNCaP cultures were negative to
staining. The alizarin red was extracted and quanti-
®ed, demonstrating that C4-2B cells had increased
levels, albeit lower than that of the osteoblasts MC
3T3-E1 levels, of alizarin red retention at 3 and 5 days
compared to LNCaP cells (Fig. 2B).
VonKossa Stainingof Prostate Cancer
Cell LineGrewin PromineralizationMedia
Osteoblasts form mineral deposits that contain
calcium and phosphate in a nodular pattern in vitro.
To determine if the calcium retention in the cells was
associated with phosphate, we performed von Kossa
staining. C4-2B cultures as young as 3-days-old were
von Kossa positive (Fig. 3A). At 20 days, von Kossa-
positive nodules were present (Fig. 3B) resemble to
that of the osteoblasts MC 3T3-E1 (Fig. 3D). In contrast,
LNCaP cultures at 3 days were negative for von Kossa
staining (not shown). Furthermore, von Kossa staining
was barely detectable in LNCaP cultures at 20 days
(Fig. 3C). These data demonstrate that C4-2B cells
Fig. 1. The calcium content increase was greater in C4-2B than
LNCaP cells when incubated in promineralization media. Cells
(C4-2B,LNCaPandMC3T3-E1)were treatedwith ( ) orwithout
(ÿ ) ascorbic acid (50 mg/ml) and b-glycerolphosphate (10 mM) for
3 (3d),10 (10d) or 20 (20d) days.Cells were then homogenized and
calcium content weremeasured by calcium assay (Sigma Chemical
Co.).Data obtained from three independentexperiments.
Fig. 2. C4-2B cells had the highest increase in calcium content
compared to LNCaP and MC3T3 cells over time. Cells (C4-2B,
LNCaP and MC 3T3-E1) were treated with ascorbic acid (50 mg/
ml) and b-glycerophosphate (10 mM) for 3 or 5 days.Calciumwas
detected using Alizarin red assay. (A) Alizarinred staining of the
cells of 5-day-old culture. (B) The intensity of themineral staining;
MC 3T3-E1 (-^-), C4-2B (-&-), and LNCaP (-~-). Data obtained
from three independentexperiments.
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have gained the ability to form mineralized nodules
in vitro.
C4-2BCells Cultured in PromineralizationMedia
ProducedHydroxyapatiticMineral
Both Raman and infrared (IR) spectroscopies were
employed in the study of mineralized tissues [16].
Raman and IR spectroscopies are complementary
techniques that probe the vibrational modes of the
various ions found in the specimen. Although IR
spectroscopy is more familiar, Raman spectroscopy
offers better spatial and spectral resolution and can be
more easily performed on highly scattering specimens
such as cell cultures or bone tissue itself. Although two
techniques probe different vibrations of a molecule
or ion, overall they provide very similar chemical
information. In the Raman spectrum of mineralized
tissue, the most prominent band is the phosphate v1
symmetric P±O stretch. This band arises from the
phosphate found in the hydroxyapatitic lattice that is
also substituted with various other ions and the band
is found in the 950±964 cmÿ 1 region. The variability in
the peak position results from the presence of a range
of ionic substituents in the apatitic lattice and also
re¯ects the crystallinity of the apatitic lattice. In bone
tissue spectra, other bands due to carbonate, mono-
hydrogen phosphate, collagen, and other matrix
proteins can be present as well.
The Raman spectrum of the C4-2B cell culture at
day 0 contained only weak bands characteristic of
the cells and the media in which they were grown
(Fig. 4A). However, the Raman spectrum of the 5-day-
old culture contained a prominent band at 958 cmÿ 1,
indicative of an apatitic mineral (Fig. 4B). For
comparison, we show a Raman spectrum of 1-day
postnatal murine calvarial tissue (Fig. 4C). The intense
apatitic phosphate P±O stretch at 958 cmÿ 1 is marked.
Other bands characteristic of phosphate, carbonate,
and normal bone matrix are visible in the spectrum.
These data con®rm that the C4-2B cells produce an
apatitic mineral.
To examine the detailed structure of the mineral
formation in individual cells, we employed TEM after
8 days of culture of the C4-2B cells in the prominer-
alization media. Mineral deposits were often seen
associated with cell membranes (Fig. 4D) as contrast to
outer matrix of the osteoblasts MC 3T3-E1 (Fig. 4E).
Fig. 3. C4-2B, but not LNCaP cells mineralized in vitro.The cells were treatedwith ascorbic acid (50 mg/ml) and b-glycerophosphate (10
mM) for (A) C4-2B, 3 days,400 magnification; (B) C4-2B, 20 days,100 magnification; (C) LNCaP, 20 days, 250 magnification; (D)MC
3T3-E1, 20days,100 magnification; andwere then fixed. Sampleswere then subjected tovonKossa staining to detectphosphate association
(indicatedby arrows).LNCaPcells showedno stainingunder the same incubation.
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Taken together, these data demonstrate that the C4-2B
cells produce bonelike mineral in vitro.
Osteoprotegerin Expression in Prostate
CancerCell Line
Two very important regulators of bone remodeling,
receptor activator of NFkB ligand (RANKL) and
osteoprotegerin (OPG), have been recently identi®ed
[17]. RANKL induces osteoclastogenesis. OPG, which
is expressed in a variety of tissues including osteo-
blasts, binds to RANKL resulting in inhibition of
osteoclastogenesis [18,19]. Thus, it follows that over-
expression of OPG by prostate cancer cells in the bone
microenvironment would inhibit osteoclast activity,
shifting the balance of bone remodeling in favor of
bone production. This could eventually lead to osteos-
clerosis. Accordingly, we determined OPG mRNA
expression in the LNCaP and C4-2B cells using real-
time PCR. The OPG PCR product-increasing rate
between two samples were similar (Fig. 5, LNCaP-
OPG vs. C4-2B-OPG). However, GAPDH level from
LNCaP entered linear elevation curve approximately
three cycles earlier than that of C4-2B (Fig. 5, LNCaP-
GAPDH vs. C4-2B-GAPDH) indicating that C4-2B
expressed higher level of OPG. These data demon-
strate that OPG is present in prostate cancer cells lines.
Expression of Genes for Bone-Related Proteins
in the ProstateCancer Cell Line
To further evaluate the extent of the osteoblastlike
phenotype in C4-2B cells, we examined cells for the
presence of alkaline phosphatase. LNCaP stained
negative whereas both C4-2B and primary human
osteoblast stained positive (Fig. 6A, B, and C,
respectively). In addition, we evaluated C4-2B for the
expression of mRNA from a variety of genes typically
expressed in osteoblasts. BSP, OCN, RANKL, and
OSN mRNA were expressed in basal conditions
(Fig. 6D). When the C4-2B cells were grown in pro-
mineralization media, BSP, OCN, RANKL, but not
OCN mRNA levels increased. These results demon-
strate that C4-2B cells share characteristics of an
osteoblast.
Cbfa1Mediates C4-2B-InducedMineralization
One potential mechanism of upregulating osteo-
blast-related proteins in prostate cancer cells is through
transcriptional activation of their gene promoters. It
has been shown that Cbfa1, a transcription factor
strongly expressed in osteoblasts and mildly in
thymus but not other tissues [20,21], plays a key role
in bone development and maturation [1]. Thus, we
Fig. 4. C4-2Bcellsproducedhydroxyapatiticmineral invitro.Ramanspectroscopyassayof cells inpromineralizationmedia for (A) control,
(B) 5-day-old culture, (C) a Raman spectrum of1daypostnatalmurine calvarial tissue; with the detection of apatiticmineral (peak 958). (D)
C4-2B and (E) MC 3T3-E1cells generatemineral showedby transmission electronmicroscopy.Cellswere cultured for 8 days under the pro-
mineralizationmedia.Cellswere thenvisualizedbyTEM (7,900 ofmagnification).Themineral deposit site is indicated (arrow).
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determined Cbfa1 expression in LNCaP and C4-2B
cells while employing human osteoblasts as positive
control. Cbfa1 mRNA and nuclear protein levels were
greater in C4-2B than LNCaP cells (Fig. 7A). Based on
this observation and the fact that Cbfa1 induces
expression of osteoblast-speci®c proteins that lead to
bone production [20,22], we next determined the effect
of inhibiting Cbfa1 activity on in vitro mineralization.
We employed a ``DNA Decoy'' strategy by introdu-
cing either wild-type or mutant Cbfa1-binding DNA
elements (Fig. 7B). Three days of promineralization
media culture increased the calcium content (``basal
aaGP'' vs. ``basal''). The mutant decoy Cbfa1-bind-
ing DNA elements did not make signi®cant decrease
of the calcium quantity (``Dec-mtAAGP'' vs.
``basal aaGP''); whereas, the wild-type decoy
Cbfa1-binding DNA elements decreased mineraliza-
tion to base line (``Dec-wtAAGP'' vs. ``basal
aaGP''). These data demonstrate that Cbfa1 is
upregulated in C4-2B cells and that C4-2B cells induce
mineralization through Cbfa1.
BMP-7 is Expressedin C4-2BCells
It is unknown how Cbfa1 is regulated in prostate
cancer cells. BMP-7 has been shown to induce Cbfa1 in
Fig. 5. C4-2B expresses higher levels of OPG mRNA than
LNCaP cells. LightCycler fluorescence detection of GAPDH of
LNCaP (-^-), C4-2B (-&-) or OPG of LNCaP (-~-), C4-2B (-x-)
mRNAby PCRof total RNA fromC4-2B or LNCaPcells.
Fig. 6. C4-2B cells express bone-relatedproteins. (A) LNCaP, (B) C4-2B and (C) primary human osteoblast cells were examined for the
activities of alkaline phosphatase (Sigma). LNCaP cells were negative, both C4-2B and primary human osteoblast stained positive (red)
(200 of magnification). (D) TargetmRNA for a variety of genes typically expressed in osteoblasts were identified by RT-PCR total RNA
fromC4-2B cultured in regular or promineralizationmedia.b2-microglobulin (b2-mGB) serves as internal control.
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cells where it is not normally expressed [23]. Accord-
ingly, we examined the expression of BMP-7 in LNCaP
and C4-2B cells while employing human osteoblasts as
positive control. Semiquantitative RT-PCR of total
RNA from 3-days-old culture of LNCaP and C4-2B,
incubated with or without promineralization medium
revealed that BMP-7 expression was only detected in
the C4-2B cells cultured in promineralization media
(Fig. 8). Thus the data demonstrated the presence
of BMP-7 in the C4-2B when stimulated by incubating
the cells in the promineralization media. This ®nding
is consistent with the ability of BMP-7 to upregulate
Cbfa1.
DISCUSSION
In the present study, we found that C4-2B prostate
cancer cells, a cell line that metastasizes to bone,
possess several aspects of an osteoblast phenotype that
are not present in its parental LNCaP cell line, which
does not metastasize to bone. This observation
suggests that prostate cancer cells gain an osteoblast-
phenotype as they progress to a metastatic tumor.
However, we cannot determine from the current
experiments if the osteoblastlike prostate cancer cells
are present prior to reaching bone or if they develop
osteoblastlike properties after they reach the bone
microenvironment. Regardless, our data also suggest
that prostate cancer cells present in skeletal metastatic
sites directly contribute to the mineral formation
found in osteoblastic lesions.
The ``seed-and-soil'' theory proposed by Paget [24]
emphasized the importance of host humoral milieu
(``soil'') that determines the selectivity of cancer
metastasis (``seed''). Bone is a composite tissue consist-
ing of inorganic mineral crystallite on a protein matrix.
The mineral component of bone consists of calcium,
phosphate, carbonate, and monohydrogen phosphate
and may include a small amount of other ions [25].
Cancer cells that migrate and invade the bone must be
able to adapt to this environment to survive and grow.
Our data suggest that to accomplish this, the pro-
state cancer cells become osteoblastlike, including the
ability to produce mineralized matrix.
The mechanism through which C4-2B cells produce
osteoblastic lesions is not currently de®ned. However,
our ®nding that OPG is increased in the C4-2B cells
compared to the LNCaP cells may provide some clues
to their effect on bone. OPG inhibits osteoclastogenesis
Fig. 7. C4-2B cells express the bone-specific transcription fac-
tor, Cbfa1 mRNA and protein. Inhibition of Cbfa1 DNA binding
cause reduced induction of calcium content by promineralization
media. (A)TotalRNA(1mg) fromLNCaP,C4-2B, andhuman osteo-
blasts were subjected to One-step RT-PCR (Gibco-BRL) to mea-
sure Cbfa1expression (upper box). Nuclear extracts (30 mg) from
LNCaP and C4-2B; and total lysate from human osteoblasts were
subjected to anti-Cbfa1 (OncogeneResearchProduct) immunoblot
to detect Cbfa1 (M.W. 60 kDa) (lower box). (B) Cells were trans-
fected with either wild-type (Dec-wt) or mutant (Dec-mt) dou-
ble-strand oligos. Cells then incubated with regular or
promineralizatio media (as indicated) for 3 days and subsequently
harvested and calciumcontentmeasured.Datawas obtained from
three independentexperiments.
Fig. 8. C4-2B cells express BMP-7 when cultured in prominera-
lization media. Total RNA (1 mg) from LNCaP, C4-2B and human
osteoblast cells cultured 3 days in regular or promineralization
(ProM) media were subjected to One-step RT-PCR (Gibco-BRL).
TheBMP-7mRNAswas solelyexpressedinC4-2BProM (upper
box). b2-microglobulin was used as an internal control (lower
box).
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[18,26]. Transgenic mice that overexpress OPG develop
severe osteopetrosis owing to the arrest of terminal
osteoclast differentiation [19]. Thus, in a similar
fashion, the expression of OPG by C4-2B may lead to
overall inhibition of osteoclast activity resulting in a
shift of bone remodeling toward osteoblast activity
resulting in osteosclerosis. However, our data also
suggest that, in addition to the C4-2B cells stimulating
osteoblasts to initiate mineralization in the bone, the
C4-2B cells themselves directly initiate mineralization
that occurs at the metastatic site.
Further evidence that the prostate cancer cells
gained an osteoblast phenotype was provided by the
observation that they expressed several osteoblast-
related noncollagenous matrix proteins including BSP,
OCN, RANKL, and OSN. This observation is consis-
tent with previous reports that osteopontin [27], OCN
[28], and BSP [29] were found to be increased in
LNCaP sublines and in human prostate cancer speci-
mens. The expression of the noncollagenous matrix
proteins may contribute to the ability of the C4-2B cells
to mineralize. Speci®cally, BSP has been shown to be a
crucial factor for the expression of osteoblastic pheno-
types of bone marrow cells cultured [30]. When
compared with nonmineralizing cells, mineralizing
subclones selectively expressed mRNAs for the osteo-
blast markers, including BSP [31]. Furthemore, OCN
and OSN are considered as the biochemical markers of
bone formation [32]. Thus, the observation that the
expression of these genes was increased in C4-2B cells
cultured in promineralization media suggests that the
bone microenvironment promotes the transition to
an osteoblast-like phenotype. Since normal prostate
epithelium does not express noncollagenous bone
matrix proteins, these data suggest that during the
malignant transformation of prostate epithelium, a
switch of gene transcription toward an osteoblast
phenotype must occur.
The observation that Cbfa1, a bone-speci®c tran-
scription factor, was elevated in the C4-2B cells may
provide the clues as to how the prostate cancer cells
gain an osteoblastlike phenotype. In mice, Cbfa1
expression occurs early during skeletal development
and is restricted to cells of mesenchymal condensa-
tions and cells that are associated with osteoblast
lineage [20]. Targeted disruption of Cbfa1 resulted in a
complete lack of bone formation and arrested osteo-
blast maturation [33]. Cbfa1 induces expression of
several bone matrix proteins expressed by osteoblasts
by binding with bone matrix protein promoters. Thus,
upregulation of Cbfa1 in the cancer cells may account
for the increased transcription of the osteoblast matrix
proteins. This postulation is supported by our obser-
vation that inhibiting Cbfa1 activity diminished the
ability of C4-2B cells to induce mineralization in vitro.
One mechanism that may account for upregulation
of Cbfa1 is BMP-7 (also called osteogenic protein-1)
expression. BMP-7, a critical mediator of bone growth
[34], induces Cbfa1 expression [23]. Our observation
that BMP-7 was increased in C4-2B cells is consistent
with the previous report that BMP-7 is present in
prostate tumors [35]. Taken together, our data suggest
that BMP-7 expression in the prostate cancer cells
induces Cbfa1, which in turn confers an osteoblast-like
phenotype.
In summary, we have observed that the C4-2B cells
gain an osteoblastlike phenotype compared to their
parental LNCaP cells. It appears that upregulation of
BMP-7 may induce Cbfa1, which in turn, induces
expression of noncollagenous matrix proteins. The
production of these proteins may account for the
ability of C4-2B cells to induce mineralization, and
thus produce osteosclerosis at skeletal metastatic sites.
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